Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 5Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7Lymphoma 4Neutropenia 3Lymphoma, Large B-Cell, Diffuse 3Testicular Neoplasms 2Testicular Germ Cell Tumor 2Multiple Myeloma 2Central Nervous System Neoplasms 2Breast Neoplasms, Male 2Triple Negative Breast Neoplasms 1Seminoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, Non-Hodgkin 1Febrile Neutropenia 1Endodermal Sinus Tumor 1Chemotherapy-induced Neutropenia 1

Interventions

pegfilgrastim 1NPI 2358 1Granulocyte Colony-Stimulating Factor 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Chemotherapy-induced Neutropenia × pegfilgrastim × Clear all
NCT03294577 2021-01-15

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 3 Unknown
221 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡